Comparison of 40% Glucose Solution and Autologous Blood Patch Pleurodesis for the Treatment of Postoperative Air Leak After Lung Resections: A Prospective Randomized Controlled Study
European Journal of Cardio-Thoracic Surgery · 2025
DOI: 10.1093/ejcts/ezaf382 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cardio-Thoracic Surgery, 2025. Verfasst von Piotr Jerzy Skrzypczak und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Poznan University of Medical Sciences, 60-569 Poznań, Poland. Hauptthemen laut MEDLINE: Pleurodesis, Pneumonectomy, Postoperative Complications, Glucose. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
Postoperative air leak is among the most common complications in thoracic surgery. Current management strategies are often suboptimal. Intrapleural administration of a glucose solution has emerged as a novel therapeutic approach; however, its clinical value has not been thoroughly investigated. This study aimed to compare the effectiveness of intrapleural 40% glucose solution vs autologous blood patch pleurodesis in managing postoperative air leak.
Methods
This prospective, randomized, controlled study enrolled patients who underwent anatomical lung resections (segmentectomy, lobectomy, or bilobectomy) at the Department of Thoracic Surgery, Poznan University of Medical Sciences, between November 2023 and December 2024. Patients with postoperative air leak were randomized to receive either 40% glucose (study group) or autologous blood (control group). The primary end-point was cessation of postoperative air leak. Secondary end-points included incidence of residual air space, chest pain, and reoperation.
Results
A total of 110 patients were included: 47 in the glucose group and 63 in the blood group. Glucose administration resulted in a higher rate of postoperative air leak resolution (95.7% vs 82.5%, P = .033; 95% CI: 2.2% to 24.2%). The glucose group had a shorter postoperative hospital stay (7 vs 9 days, P = .036). Chest pain occurred more frequently in the glucose group, but the difference was not statistically significant (10.6% vs 4.8%, P = .24). No major infectious complications were observed. Residual air space occurrence and reoperation rates were comparable.
Conclusions
Intrapleural 40% glucose solution achieved a higher resolution rate of postoperative air leak compared to autologous blood patch pleurodesis, with a comparable safety profile. Clinical Registration Number NCT06936969 (ClinicalTrials.gov).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Poznan University of Medical Sciences, 60-569 Poznań, Poland.
ORCID-Profile: Piotr Jerzy Skrzypczak, Piotr Gabryel
Zitieren
APA
Skrzypczak, P. J., Dobiecki, T., Rozmiarek, M., Gabryel, P., Kasprzyk, M., & Piwkowski, C. (2025). Comparison of 40% Glucose Solution and Autologous Blood Patch Pleurodesis for the Treatment of Postoperative Air Leak After Lung Resections: A Prospective Randomized Controlled Study. European Journal of Cardio-Thoracic Surgery. https://doi.org/10.1093/ejcts/ezaf382
Vancouver
Skrzypczak PJ, Dobiecki T, Rozmiarek M, Gabryel P, Kasprzyk M, Piwkowski C. Comparison of 40% Glucose Solution and Autologous Blood Patch Pleurodesis for the Treatment of Postoperative Air Leak After Lung Resections: A Prospective Randomized Controlled Study. European Journal of Cardio-Thoracic Surgery. 2025. doi:10.1093/ejcts/ezaf382
BibTeX
@article{Skrzypczak2025,
author = {Skrzypczak, Piotr Jerzy and Dobiecki, Tomasz and Rozmiarek, Monika and Gabryel, Piotr and Kasprzyk, Mariusz and Piwkowski, Cezary},
title = {Comparison of 40% Glucose Solution and Autologous Blood Patch Pleurodesis for the Treatment of Postoperative Air Leak After Lung Resections: A Prospective Randomized Controlled Study},
journal = {European Journal of Cardio-Thoracic Surgery},
year = {2025},
doi = {10.1093/ejcts/ezaf382}
}
EUVIMED